Drug Discovery
Our drug discovery group specializes in cancer and central nervous system drug research. Several major products including Taxol have been discovered at RTI, and we currently have several compounds in clinical trials. Our drug discovery team has expertise in pharmacology, synthetic chemistry, modeling, analytical, and identification techniques. Our extensive laboratory facilities give us the ability to support multiple client projects to satisfy our clients' drug discovery programs.
Focus Areas
- Chemical Synthesis and Characterization
Camptothecins, cannabinoids, morphans, phenylamines, steroids, tropanes - Pharmacology and Bioassays
Anticancer and central nervous system pharmacology; cystic fibrosis; molecular biology - Chemoinformatics
Electronic databases describing the chemistry, biology, and effects of compounds from more than 40 years of synthetic and natural products chemistry at RTI - Natural Products Research
Bioactive compounds in plants, bacteria, and fungi; anticancer, antifungal, antibacterial, and central nervous system drug discovery; herbal supplements and their interactions with cancer and conventional cancer treatments
Capabilities
- Traditional, rational drug design methodologies
- Combinatorial/array methodologies
- Radiosynthesis
- Nuclear magnetic resonance
- Array synthesis
rti.orgRelated Content
UMBI President Jennie Hunter-Cevera to Join RTI International as Executive Vice President of Discovery and Analytical Sciences, Corporate Development
Jennie Hunter-Cevera, Ph.D., a distinguished scientist, business leader and the current president and CEO of the University of Maryland Biotechnology Institute (UMBI), will join RTI International July 1, as Executive Vice President of Discovery and Analytical Sciences and Corporate Development.